41 results found.

Neuroendocrine Neoplasms, Thyroid Neoplasms, Parathyroid Neoplasm Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting 7 years or older.
- Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms.

Recurrent Neuroblastoma Clinical Trial using temozolomide; irinotecan hydrochloride; temsirolimus; monoclonal antibody Ch14.18; sargramostim; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting N/A or older.
- A Phase II Randomized Trial of Irinotecan/Temozolomide With Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (ch14.18) (NSC# 623408) in Children With Refractory, Relapsed or Progressive Neuroblastoma.
temozolomide; irinotecan hydrochloride; temsirolimus; monoclonal antibody Ch14.18; sargramostim; laboratory biomarker analysis

Neuroblastoma Recurrent Clinical Trial using Dasatinib; Rapamycin; Irinotecan; Temozolomide

University of Regensburg - Recruiting N/A to 25 years.
- Prospective, Open Label, Randomized Phase II Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-risk Neuroblastoma.
Dasatinib; Rapamycin; Irinotecan; Temozolomide

Brain and Central Nervous System Tumors, Intraocular Melanoma, Lu Clinical Trial using DNA analysis; immunologic technique; pharmacological study; iodine I 131 monoclonal antibody 3F8; 131I-3F8

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Phase II Study of Intrathecal I-3F8 in Patients With GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms.
DNA analysis; immunologic technique; pharmacological study; iodine I 131 monoclonal antibody 3F8; 131I-3F8

Leukemia, Lymphoma, Neuroblastoma, Sarcoma, or Desmoplastic Small Clinical Trial using Melphalan; Fludarabine; Cyclophosphamide; Cytarabine; Prednisone; Vincristine; Doxorubicin; Etoposide; Filgrastim; NK-DLI Infusions

National Institutes of Health Clinical Center (CC) - Recruiting 4 years to 35 years.
- A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias.
Melphalan; Fludarabine; Cyclophosphamide; Cytarabine; Prednisone; Vincristine; Doxorubicin; Etoposide; Filgrastim; NK-DLI Infusions

Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma, or Brain Tumo Clinical Trial using plerixafor

Sanofi - Recruiting 1 year to 18 years.
- A Phase 1/2 Combined Dose Ranging and Randomized, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilization of Haematopoietic Stem Cells Into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilization Regimens Alone in Pediatric Patients, Aged 1 to <18 Years, With Solid Tumours Eligible for Autologous Transplants..
plerixafor

Sarcoma, Endocrine Tumors, Neuroblastoma, Retinoblastoma, or Rena Clinical Trial

National Institutes of Health Clinical Center (CC) - Recruiting N/A or older.
- Comprehensive Omics Analysis of Pediatric Solid Tumors and Establishment of a Repository for Related Biological Studies.

Neuroblastoma;, Rhabdomyosarcoma;, Ewing's Sarcoma;, Ewing's Tumo Clinical Trial using nab-paclitaxel

Celgene Corporation - Recruiting 6 Months to 21 years.
- A Phase 1 / 2, Multicenter, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent or Refractory Solid Tumors.
nab-paclitaxel

Neuroblastoma, or Bone Marrow, Sympathetic Nervous System Clinical Trial using cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Phase I Study of Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma.
cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8

Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, L Clinical Trial using laboratory biomarker analysis; polymerase chain reaction; polyacrylamide gel electrophoresis; DNA analysis

Children's Oncology Group - Recruiting N/A or older.
- Analysis of Circulating MYCN DNA in Serum Samples Obtained From Patients With Neuroblastoma.
laboratory biomarker analysis; polymerase chain reaction; polyacrylamide gel electrophoresis; DNA analysis

Neuroblastoma Clinical Trial using laboratory biomarker analysis; cytology specimen collection procedure; questionnaire administration

Children's Oncology Group - Recruiting N/A or older.
- Genetic Susceptibility Factors in the Etiology of Neuroblastoma Also Known as Neuroblastoma Epidemiology in North America (NENA).
laboratory biomarker analysis; cytology specimen collection procedure; questionnaire administration

Disseminated Neuroblastoma, Localized Resectable Neuroblastoma, L Clinical Trial using laboratory biomarker analysis; cytology specimen collection procedure

Children's Oncology Group - Recruiting N/A to 30 years.
- Neuroblastoma Biology Studies.
laboratory biomarker analysis; cytology specimen collection procedure

Neuroblastoma Clinical Trial using 3F8 Monoclonal Antibody Combined with Interleukin-2

Memorial Sloan-Kettering Cancer Center - Recruiting 13 Months or older.
- Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors.
3F8 Monoclonal Antibody Combined with Interleukin-2

Disseminated Neuroblastoma, Localized Unresectable Neuroblastoma, Clinical Trial using vorinostat; isotretinoin; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting N/A to 30 years.
- Phase I Study of Vorinostat in Combination With 13-Cis-Retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma.
vorinostat; isotretinoin; pharmacological study; laboratory biomarker analysis

Neuroblastoma, or Medulloblastoma Clinical Trial using Nifurtimox; Cyclophosphamide; Topotecan

Spectrum Health Hospitals - Recruiting N/A to 21 years.
- A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma..
Nifurtimox; Cyclophosphamide; Topotecan

Neuroblastoma, Medulloblastoma, Brain Tumors, or Rare Tumors Clinical Trial using Guided Therapy- Pediatric Gene Analysis Platform

Spectrum Health Hospitals - Recruiting 13 Months or older.
- A Feasibility Trial Using Molecular-Guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancer.
Guided Therapy- Pediatric Gene Analysis Platform

Neuroblastoma Clinical Trial using TPI 287; Temozolomide; Irinotecan

Spectrum Health Hospitals - Recruiting 12 Months to 21 years.
- A Randomized, Phase I/II Trial of Irinotecan and Temozolomide Compared to Irinotecan and Temozolomide in Combination With TPI 287 in Patients With Primary Refractory or Early Relapsed Neuroblastoma.
TPI 287; Temozolomide; Irinotecan

Neuroblastoma Clinical Trial using iC9-GD2 T Cell Lymphocytes

Baylor College of Medicine - Recruiting N/A or older.
- AUTOLOGOUS ACTIVATED T-CELLS TRANSDUCED WITH A 3rd GENERATION GD-2 CHIMERIC ANTIGEN RECEPTOR AND iCASPASE9 SAFETY SWITCH ADMINISTERED TO PATIENTS WITH RELAPSED OR REFRACTORY NEUROBLASTOMA (GRAIN).
iC9-GD2 T Cell Lymphocytes

Recurrent or Refractory Solid Tumors, Ewing Sarcoma, Rhabdomyosar Clinical Trial using MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide

Merrimack Pharmaceuticals - Recruiting 12 Months to 20 years.
- Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors.
MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide

Sarcoma, Wilm's Tumor, Lymphoma, or Neuroblastoma Clinical Trial using Ipilimumab(anti-CTLA-4 antibody)

National Institutes of Health Clinical Center (CC) - Recruiting 1 year to 21 years.
- A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults With Treatment Refractory Cancer.
Ipilimumab(anti-CTLA-4 antibody)

Malignant Rhabdoid Tumors (MRT), Neuroblastoma Clinical Trial using LEE011

Novartis - Recruiting 1 year to 21 years.
- A Phase I, Multi-center, Open-label Study of LEE011 in Patients With Malignant Rhabdoid Tumors and Neuroblastoma.
LEE011

Neuroblastoma, or Sarcoma Clinical Trial using Cyclophosphamide, Topotecan, and Bevacizumab

Memorial Sloan-Kettering Cancer Center - Recruiting N/A to 21 years.
- A Phase II Trial of Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma.
Cyclophosphamide, Topotecan, and Bevacizumab

Childhood Langerhans Cell Histiocytosis, Fanconi Anemia, Leukemia Clinical Trial using anti-thymocyte globulin; busulfan; cyclophosphamide; fludarabine phosphate; melphalan; methylprednisolone; radiation therapy

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- The Use Of Umbilical Cord Blood As A Source Of Hematopoietic Stem Cells.
anti-thymocyte globulin; busulfan; cyclophosphamide; fludarabine phosphate; melphalan; methylprednisolone; radiation therapy

Neuroblastoma Clinical Trial using DFMO; Celecoxib; Cyclophosphamide; Topotecan

New Approaches to Neuroblastoma Therapy Consortium - Recruiting 2 years to 30 years.
- N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan for Patients With Relapsed or Refractory Neuroblastoma.
DFMO; Celecoxib; Cyclophosphamide; Topotecan

Brain and Central Nervous System Tumors, Neuroblastoma, or Sarcom Clinical Trial using iodine I 131 monoclonal antibody 8H9

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- Phase I Study Of Intrathecal Radioimmunotherapy Using I-8H9 For Central Nervous System/Leptomeningeal Neoplasms.
iodine I 131 monoclonal antibody 8H9

Neuroblastoma Clinical Trial using adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH

Memorial Sloan-Kettering Cancer Center - Recruiting N/A to 21 years.
- Phase I/II Trial of a Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral á-glucan for High-Risk Neuroblastoma.
adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH

Neuroblastoma in Remission Clinical Trial using DFMO

Spectrum Health Hospitals - Recruiting N/A to 21 years.
- A Phase II Preventative Trial of DFMO as a Single Agent in Patients With High Risk Neuroblastoma in Remission.
DFMO

Neuroblastoma Clinical Trial

New Approaches to Neuroblastoma Therapy Consortium - Recruiting N/A or older.
- N2004-05: Neuroblastoma Biology Study.

Neuroblastoma, or Medulloblastoma Clinical Trial using TPI 287

Spectrum Health Hospitals - Recruiting 12 Months to 30 years.
- A Phase I/II Trial of TPI-287 in Patients With Refractory or Recurrent Neuroblastoma and Medulloblastoma.
TPI 287

Medulloblastoma,, Rhabdomyosarcoma,, Neuroblastoma,, Hepatoblasto Clinical Trial using LDE225

Novartis - Recruiting 12 Months to 18 years.
- A Phase I/II Study of LDE225 in Pediatric Patients With Recurrent or Refractory Medulloblastoma or Other Tumors Potentially Dependent on the Hedgehog-signaling Pathway and Adult Patients With Recurrent or Refractory Medulloblastoma.
LDE225

Neuroblastoma Clinical Trial using isotretinoin; DNA analysis; polymerase chain reaction; laboratory biomarker analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting N/A to 18 years.
- Pilot Study to Investigate the Feasibility of 13-cis-retinoic Acid Pharmacokinetic Monitoring in High-risk Neuroblastoma Patients.
isotretinoin; DNA analysis; polymerase chain reaction; laboratory biomarker analysis; pharmacological study

Neuroblastoma Clinical Trial using filgrastim; carboplatin; cisplatin; cyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide phosphate; ifosfamide; isotretinoin; melphalan; topotecan hydrochloride; vincristine sulfate; vindesine; autologous hematopoietic stem cell transplantation; conventional surgery; peripheral blood stem cell transplantation; iobenguane I 131; radiation therapy

National Cancer Institute (NCI) - Recruiting N/A to 21 years.
- NB2004 Trial Protocol for Risk Adapted Treatment of Children With Neuroblastoma.
filgrastim; carboplatin; cisplatin; cyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide phosphate; ifosfamide; isotretinoin; melphalan; topotecan hydrochloride; vincristine sulfate; vindesine; autologous hematopoietic stem cell transplantation; conventional surgery; peripheral blood stem cell transplantation; iobenguane I 131; radiation therapy

Neuroblastoma Clinical Trial using buthionine sulfoximine; melphalan; Peripheral blood stem cell infusion; Filgrastim

New Approaches to Neuroblastoma Therapy Consortium - Recruiting N/A to 30 years.
- Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) Autologous Stem Cell Support for Resistant or Recurrent High-Risk Neuroblastoma (IND 69-112).
buthionine sulfoximine; melphalan; Peripheral blood stem cell infusion; Filgrastim

Sarcoma, Neuroblastoma, Wilms Tumor, Leukemia, Lymphoma, or Brain Clinical Trial using Marqibo

Spectrum Pharmaceuticals, Inc - Recruiting 2 years to 20 years.
- Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer.
Marqibo

Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Clinical Trial using crizotinib; pharmacogenomic studies; pharmacological study

National Cancer Institute (NCI) - Recruiting 1 year to 21 years.
- A Phase I/II Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-Met, in Children With Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma.
crizotinib; pharmacogenomic studies; pharmacological study

Neuroblastoma Clinical Trial

National Taiwan University Hospital - Recruiting N/A or older.
- The Effect of Nurse Case Manager Model on Caregiver's Adaptation of Disease Uncertainty About Their Child With Neuroblastoma.

Neuroblastoma Clinical Trial using Tri-virus specific cytotoxic t-cells

Children's Mercy Hospital Kansas City - Recruiting 18 Months to 17 years.
- Phase I Study of Donor Derived,Gene Modified, Multi-virus-specific, Cytotoxic T-Lymphocytes Redirected to the Tumor Marker GD2 for Relapsed/Refractory Neuroblastoma Post-allogeneic Stem Cell Transplantation With a Submyeloblative Conditioning Regimen.
Tri-virus specific cytotoxic t-cells

Neuroblastoma Clinical Trial using Reduced-intensity allogeneic hematopoietic stem cell transplantation

Samsung Medical Center - Recruiting N/A to 20 years.
- Allogeneic Hematopoietic Stem Cell Transplantation With Reduced-intensity Conditioning in Children With Neuroblastoma Who Have Failed a Prior Autologous Transplantation.
Reduced-intensity allogeneic hematopoietic stem cell transplantation

Neuroblastoma Clinical Trial using tandem high-dose chemotherapy

Samsung Medical Center - Recruiting N/A or older.
- Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma.
tandem high-dose chemotherapy

Neuroblastoma, Brain Tumors, or Solid Tumors Clinical Trial using Temozolomide/Hycamtin (Topotecan)

Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 6 Months to 20 years.
- Phase 2 Single- Arm Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Neuroblastoma and Other Paediatric Solid Tumours.
Temozolomide/Hycamtin (Topotecan)

Neuroblastoma, or Opsoclonus-Myoclonus Clinical Trial using anti-CD20 (Rituximab)

Tersak, Jean M., M.D. - Recruiting 2 Months to 18 years.
- Use of Rituximab in Opsoclonus-Myoclonus in Children With Neuroblastoma.
anti-CD20 (Rituximab)